跳至主要内容
临床试验/NCT03416309
NCT03416309Unknown不适用

Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response

University of Turin, Italy1 个研究点 分布在 1 个国家目标入组 257 人开始时间: 2017年5月25日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
257
试验地点
1
主要终点
Correlation between AUC of RHZE and TTP

研究概览

简要总结

The aim of the study is to investigate the possible correlation of plasma drug concentrations with Time To Positivity (TTP) in liquid culture in patients with active pulmonary multi sensitive TB in the first two weeks of treatment. Secondary aims are: the correlation between plasma drug concentrations and hepato/neuro toxicity; the impact of different allelic variants on PK data, toxicity and TTP in liquid culture; the feasibility of using dried blood/plasma spots to measure plasma concentrations of anti-TB drugs and determine genetic polymorphisms.

详细描述

A longitudinal observational multicentred study will be conducted in patients with diagnosis of active pulmonary TB.

The following variables will be recorded:

  • demographic variables: age, gender, ethnicity, SNPs for NAT2, SLCO1B1, ABCB1 and VDR;
  • clinical variables: weight, height, renal function tests, liver function tests, vitamin D (25-OH vitamin D) level, albuminemia, serology for HIV, HCV, presence of comorbidities (e.g. diabetes mellitus), visual acuity test, presence of neuropathic symptoms;
  • microbiological variables: phenotypic and genotypic drug sensitivity test results, sputum Mycobacterium tuberculosis DNA (PCR), microscopy, culture, Time To Positivity (TTP) in liquid culture, IGRA test (if performed), history of previous treatments, location of pulmonary lesions, presence of extra-pulmonary locations;
  • therapeutic variables: start/end of treatment, treatment interruptions, dose mg/kg, route of administration.

The patients will received standard antitubercular drugs according to international guidelines (RIF 10 mg/kg, INH 5 mg/kg maximum dose 300 mg, ETB 15-20 mg/kg, PZA 25 mg/kg maximum dose 2000 mg) in fasten condition, once daily.

To measure plasma concentrations four blood samples (Lithium heparin 7 ml tubes) will be collected at 0, 2, 4 and 6 hours post dose. This analysis will be performed at 7 and 14 days after the beginning of anti-TB treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • signed informed consent
  • age >=18 years;
  • pulmonary tuberculosis defined by positive sputum microscopy (waiting for culture confirmation)
  • sensitivity to first-line anti-TB drugs;
  • normal liver and renal function.

排除标准

  • severe malnutrition;
  • HIV infection

结局指标

主要结局

Correlation between AUC of RHZE and TTP

时间窗: 2 weeks from start of treatment

Investigate the correlation of plasma drug concentrations (Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, HRZE) with the change in Time To Positivity (TTP) in liquid culture in patients with active pulmonary TB between the baseline and the second week of treatment.

次要结局

  • Correlation between AUC of RHZE and toxicity(1 week and 2 weeks from start of treatment)
  • Assess the consistency of results using of DPS for measuring the plasma drug concentrations(1 week and 2 weeks from start of treatment)
  • Correlate AUC of RHZE with antiTB response(6 months after end of treatment)
  • Correlate PG with antiTB response(6 months after end of treatment)
  • Correlation between PG and AUC of RHZE(1 week and 2 weeks from start of treatment)

研究者

发起方
University of Turin, Italy
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ilaria Motta

Principal Investigator

University of Turin, Italy

研究点 (1)

Loading locations...

相似试验